Lytix Biopharma Announces Presentation of Interim Data from ATLAS-IT-05 Study at ESMO 2023

Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, today announces that an abstract with clinical data from the ATLAS-IT-05 study is accepted for presentation at ESMO 2023.

In ATLAS-IT-05, a Phase II study, LTX-315 is given to patients with advanced melanoma in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda), a market leading approved immunotherapeutic antibody. In the abstract interim efficacy and safety data from the first patients enrolled in the Phase II study are presented.

The interim data will be presented by the leading investigator of the trial, Professor Stéphane Dalle (Centre Hospitalier Universitaire de Lyon, France) in a poster session. The poster title is: Intratumoral injection of LTX-315 in combination with pembrolizumab in patients with advanced melanoma refractory to prior PD-1/PD-L1 therapy: interim results from the ATLAS-IT-05 trial.

Øystein Rekdal, CEO of Lytix commented: “We are looking forward to sharing interim data from the ongoing ATLAS-IT-05 trial at this year’s ESMO in Madrid. The study is running at several sites in the US and Europe exploring the ability of LTX-315 to alter the course of disease in patients who have previously failed treatment with anti-PD-1/PDL-1.”

For more information about ATLAS-IT-05:

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.
This new collaboration is another example of Blacksmith's creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products.
Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.
Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.
Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics. "We are very pleased to announce the Notice of Allowance for our second patent, which will enhance the long-term value of ST-62516. Saghmos continues to build its intellectual property estate."

By using this website you agree to accept Medical Device News Magazine Privacy Policy